Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023

  • ID: 4607081
  • Report
  • Region: Global
  • 191 Pages
  • Markets and Markets
1 of 6
The Vaccines Market is Expected to Reach USD 50.42 Billion by 2023 from USD 36.45 Billion in 2018, at a CAGR of 6.7%

FEATURED COMPANIES

  • Astellas Pharma
  • Biological E
  • Daiichi Sankyo Company
  • Glaxosmithkline
  • Merck
  • Pfizer
  • MORE

“Global vaccines market projected to grow at a CAGR of 6.7%”

The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development.

“Monovalent vaccines segment expected to hold the largest share of the market in 2018.”

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.

“Pneumococcal disease segment is expected to hold largest share of the market in 2018”

Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share of the vaccines market in 2018. The large share of this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal diseases.

“Asia to witness high growth during the forecast period”

In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 – 36%; Tier 2 - 41%; Tier 3 - 23%.
  • By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
  • By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
  • By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report

  • GlaxoSmithKline plc (US)
  • Pfizer, Inc. (US)
  • Merck & Co., Inc. (US)
  • Sanofi Pasteur SA (France)
  • CSL Limited (Australia)
  • Emergent BioSolutions, Inc. (US)
  • Johnson & Johnson (US)
  • MedImmune, LLC (US)
  • Astellas Pharma Inc. (Japan)
  • Serum Institute of India (India)
  • Bavarian Nordic (Denmark)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Biological E (India)
  • Panacea Biotec (India)

Research Coverage:

The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Astellas Pharma
  • Biological E
  • Daiichi Sankyo Company
  • Glaxosmithkline
  • Merck
  • Pfizer
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Overview of the Vaccines Market
4.2 By Type, 2018–2023
4.3 By End User, 2018 vs 2023 (USD Billion)
4.4 Geographic Analysis: By Technology
4.5 By Route of Administration, 2018 vs 2023 (USD Billion)
4.6 Geographical Snapshot of the Global Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus on Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus on Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.4.2 Product Recalls

6 Industry Insights
6.1 Regulatory Landscape
6.1.1 North America
6.1.2 Europe
6.1.3 Asia
6.1.4 RoW
6.2 Key Pipeline Products
6.3 New Vaccine Opportunities
6.3.1 Hiv
6.3.1.1 HIV Vaccine: Product Pipeline
6.3.1.2 HIV Vaccine: Public-Private Initiatives
6.3.1.3 HIV Vaccine: Funding
6.3.2 Malaria
6.3.2.1 Malaria Vaccine: Product Pipeline
6.3.2.2 Malaria Vaccine: Public-Private Initiatives
6.3.3 Zika
6.3.3.1 Zika Vaccine: Product Pipeline
6.3.3.2 Zika Vaccine: Public-Private Initiatives
6.3.3.3 Zika Vaccine: Funding
6.3.4 Ebola
6.3.4.1 Ebola Vaccine: Product Pipeline
6.3.4.2 Ebola Vaccine: Public-Private Initiatives
6.3.4.3 Ebola Vaccine: Funding

7 Vaccines Market, By Technology
7.1 Introduction
7.2 Conjugate Vaccines
7.3 Inactivated and Subunit Vaccines
7.4 Live Attenuated Vaccines
7.5 Recombinant Vaccines
7.6 Toxoid Vaccines

8 By Type
8.1 Introduction
8.2 Monovalent Vaccines
8.3 Multivalent Vaccines

9 By Disease Indication
9.1 Introduction
9.2 Pneumococcal Disease
9.3 DTP
9.4 Influenza
9.5 HPV
9.6 Meningococcal Disease
9.7 Polio
9.8 Rotavirus
9.9 Hepatitis
9.10 MMR
9.11 Varicella
9.12 Dengue
9.13 Herpes Zoster
9.14 Other Disease Indications

10 By Route of Administration
10.1 Introduction
10.2 Intramuscular and Subcutaneous Administration
10.3 Oral Administration
10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type
11.1 Introduction
11.2 Pediatric Patients
11.3 Adult Patients

12 By Region
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 RoE
12.4 Asia
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Rest of Asia (Roa)
12.5 Rest of the World (RoW)

13 Competitive Landscape
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Situation and Trends
13.3.1 Agreements, Partnerships, and Collaborations
13.3.2 Product Launches and Approvals
13.3.3 Acquisitions
13.3.4 Expansions

14 Company Profiles
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 Pfizer
14.2 Glaxosmithkline
14.3 Merck
14.4 Sanofi Pasteur
14.5 CSL Limited
14.6 Emergent Biosolutions
14.7 Johnson & Johnson
14.8 Medimmune, LLC (A Subsidiary of Astrazeneca)
14.9 Astellas Pharma
14.10 Serum Institute of India
14.11 Bavarian Nordic
14.12 Mitsubishi Tanabe Pharma Corporation
14.13 Daiichi Sankyo Company
14.14 Panacea Biotec
14.15 Biological E
*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

15 Appendix
15.1 Discussion Guide
15.2 Knowledge Store: Subscription Portal
15.3 Available Customizations
15.4 Related Reports
15.5 Author Details

List of Tables
Table 1 Incidence of Diseases
Table 2 NIH Funding for Vaccine Research, 2013–2018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2015 vs 2016
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Estimated Investments in HIV Vaccines, By Investor (2015–2016)
Table 8 Ebola Projects Funded By Ec (2014–2020)
Table 9 By Technology, 2016–2023 (USD Million)
Table 10 Cost of Meningococcal Conjugate Vaccines
Table 11 Conjugate Vaccines Market, By Region, 2016–2023 (USD Million)
Table 12 Examples of Inactivated and Subunit Vaccines
Table 13 Inactivated and Subunit Vaccines Market, By Region, 2016–2023 (USD Million)
Table 14 Live Attenuated Vaccines, By Region, 2016–2023 (USD Million)
Table 15 Examples of Recombinant Vaccines
Table 16 Recombinant Vaccines, By Region, 2016–2023 (USD Million)
Table 17 Toxoid Vaccines, By Region, 2016–2023 (USD Million)
Table 18 By Type, 2016–2023 (USD Million)
Table 19 Monovalent Vaccines Market, By Region, 2016–2023 (USD Million)
Table 20 Examples of Notable Multivalent Vaccines Available in the Market
Table 21 Multivalent Vaccines Market, By Region, 2016–2023 (USD Million)
Table 22 By Disease Indication, 2016–2023 (USD Million)
Table 23 List of Commercially Available Pneumococcal Vaccines in the Market
Table 24 Vaccines Market for Pneumococcal Disease, By Region, 2016–2023 (USD Million)
Table 25 List of Commercially Available DTP Vaccines in the Market
Table 26 Market for DTP, By Region, 2016–2023 (USD Million)
Table 27 List of Commercially Available Influenza Vaccines in the Market
Table 28 Market for Influenza, By Region, 2016–2023 (USD Million)
Table 29 List of Commercially Available HPV Vaccines in the Market
Table 30 Market for HPV, By Region, 2016–2023 (USD Million)
Table 31 List of Commercially Available HPV Vaccines in the Market
Table 32 Market for Meningococcal Disease, By Region, 2016–2023 (USD Million)
Table 33 List of Commercially Available Polio Vaccines in the Market
Table 34 Market for Polio, By Region, 2016–2023 (USD Million)
Table 35 List of Commercially Available Rotavirus Vaccines in the Market
Table 36 Market for Rotavirus, By Region, 2016–2023 (USD Million)
Table 37 List of Commercially Available Hepatitis Vaccines in the Market
Table 38 Market for Hepatitis, By Region, 2016–2023 (USD Million)
Table 39 List of Commercially Available MMR Vaccines in the Market
Table 40 Market for MMR, By Region, 2016–2023 (USD Million)
Table 41 List of Commercially Available Varicella Vaccines in the Market
Table 42 Market for Varicella, By Region, 2016–2023 (USD Million)
Table 43 Market for Herpes Zoster, By Region, 2016–2023 (USD Million)
Table 44 List of Commercially Available Vaccines for Other Disease Indications in the Market
Table 45 Market for Other Disease Indications, By Region, 2016–2023 (USD Million)
Table 46 By Route of Administration, 2016–2023 (USD Million)
Table 47 Market for Intramuscular and Subcutaneous Administration, By Region, 2016–2023 (USD Million)
Table 48 Vaccines Market for Oral Administration, By Region, 2016–2023 (USD Million)
Table 49 Market for Other Routes of Administration, By Region, 2016–2023 (USD Million)
Table 50 By Patient Type, 2016–2023 (USD Million)
Table 51 Vaccines Market for Pediatric Patients, By Region, 2016–2023 (USD Million)
Table 52 North America: Market for Pediatric Patients, By Country, 2016–2023 (USD Million)
Table 53 Vaccines Market for Adult Patients, By Region, 2016–2023 (USD Million)
Table 54 North America: Market for Adult Patients, By Country, 2016–2023 (USD Million)
Table 55 By Region, 2016–2023 (USD Million)
Table 56 North America: Market, By Country, 2016–2023 (USD Million)
Table 57 North America: Market, By Technology, 2016–2023 (USD Million)
Table 58 North America: Market, By Type, 2016–2023 (USD Million)
Table 59 North America: Market, 2016–2023 (USD Million)
Table 60 North America: Market, 2016–2023 (USD Million)
Table 61 North America: Market, By Patient Type, 2016–2023 (USD Million)
Table 62 US: Market, By Technology, 2016–2023 (USD Million)
Table 63 US: Market, By Patient Type, 2016–2023 (USD Million)
Table 64 Canada: Market, By Technology, 2016–2023 (USD Million)
Table 65 Canada: Market, By Patient Type, 2016–2023 (USD Million)
Table 66 Europe: Market, By Country, 2016–2023 (USD Million)
Table 67 Europe: Market, By Technology, 2016–2023 (USD Million)
Table 68 Europe: Market, By Type, 2016–2023 (USD Million)
Table 69 Europe: Market, By Disease Indication, 2016–2023 (USD Million)
Table 70 Europe: Market, By Route of Administration, 2016–2023 (USD Million)
Table 71 Europe: Market, By Patient Type, 2016–2023 (USD Million)
Table 72 Germany: Market, By Technology, 2016–2023 (USD Million)
Table 73 UK: Market, By Technology, 2016–2023 (USD Million)
Table 74 France: Market, By Technology, 2016–2023 (USD Million)
Table 75 Italy: Market, By Technology, 2016–2023 (USD Million)
Table 76 Spain: Market, By Technology, 2016–2023 (USD Million)
Table 77 RoE: Market, By Technology, 2016–2023 (USD Million)
Table 78 Asia: Health Expenditure Per Capita, By Country, 2000, 2014 & 2016 (USD)
Table 79 Asia: Market, By Country, 2016–2023 (USD Million)
Table 80 Asia: Market, By Technology, 2016–2023 (USD Million)
Table 81 Asia: Market, By Type, 2016–2023 (USD Million)
Table 82 Asia: Market, By Disease Indication, 2016–2023 (USD Million)
Table 83 Asia: Market, By Route of Administration, 2016–2023 (USD Million)
Table 84 Asia: Market, By Patient Type, 2016–2023 (USD Million)
Table 85 Japan: Market, By Technology, 2016–2023 (USD Million)
Table 86 China: Market, By Technology, 2016–2023 (USD Million)
Table 87 India: Market, By Technology, 2016–2023 (USD Million)
Table 88 RoA: Market, By Technology, 2016–2023 (USD Million)
Table 89 RoW:  Market, By Technology, 2016–2023 (USD Million)
Table 90 RoW: Market, By Type, 2016–2023 (USD Million)
Table 91 RoW: Market, 2016–2023 (USD Million)
Table 92 RoW: Market, 2016–2023 (USD Million)
Table 93 RoW: Market, By Patient Type, 2016–2023 (USD Million)

List of Figures
Figure 1 Market Segmentation
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 By Technology, 2018–2023
Figure 7 By Type, 2018 vs 2023 (USD Billion)
Figure 8 By Disease Indication, 2018 vs 2023 (USD Billion)
Figure 9 By Route of Administration, 2018 vs 2023 (USD Billion)
Figure 10 By Patient Type, 2018 vs 2023 (USD Billion)
Figure 11 Geographical Snapshot of the Global Market
Figure 12 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 13 Monovalent Vaccines Segment to Register the Highest Growth During the Forecast Period
Figure 14 Pediatrics Segment to Dominate the global Market in 2023 (USD Billion)
Figure 15 Conjugate Vaccines Segment to Hold Largest Share of the Market in 2018
Figure 16 Intramuscular and Subcutaneous Administration Segment to Register the Highest Growth During the Forecast Period
Figure 17 US to Dominate the Global Market in 2018
Figure 18 Vaccine Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Regulatory Approval Process for Vaccines
Figure 20 R&D Funding for HIV Preventive Vaccines, By Investor, 2016
Figure 21 Conjugate Vaccines Segment to Dominate the Market During the Forecast Period
Figure 22 Monovalent Vaccines to Grow at the Highest Rate in the Market, By Type
Figure 23 Pneumococcal Disease Segment to Lead Market, By Disease Indication, During 2018–2023
Figure 24 Vaccines Market for Dengue, 2016–2023 (USD Million)
Figure 25 Intramuscular and Subcutaneous Administration Segment to Account for the Market, 2018–2023 (USD Million)
Figure 26 Pediatric Patients Segment to Account for the Largest Share of the Global Market, 2018 (USD Million)
Figure 27 North America: Vaccines Market Snapshot
Figure 28 Europe: Vaccines Market Snapshot
Figure 29 Asia: Vaccines Market Snapshot
Figure 30 RoW: Vaccines Market Snapshot
Figure 31 Key Developments in the Vaccine Market From 2015 to 2018
Figure 32 Market Evolution Framework
Figure 33 Vaccines Market Share Analysis, By Key Player, 2017
Figure 34 Pfizer: Company Snapshot (2017)
Figure 35 Glaxosmithkline: Company Snapshot (2017)
Figure 36 Merck: Company Snapshot (2017)
Figure 37 Sanofi Pasteur: Company Snapshot (2017)
Figure 38 CSL Limited: Company Snapshot (2017)
Figure 39 Emergent Biosolutions: Company Snapshot (2017)
Figure 40 Johnson & Johnson: Company Snapshot (2017)
Figure 41 Astrazeneca: Company Snapshot (2017)
Figure 42 Astellas Pharma: Company Snapshot (2017)
Figure 43 Bavarian Nordic: Company Snapshot (2017)
Figure 44 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2017)
Figure 45 Daiichi Sankyo Company: Company Snapshot (2017)
Figure 46 Panacea Biotec: Company Snapshot (2017)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Astellas Pharma
  • Bavarian Nordic
  • Biological E
  • CSL Limited
  • Daiichi Sankyo Company
  • Emergent Biosolutions
  • Glaxosmithkline
  • Johnson & Johnson
  • Medimmune, LLC (A Subsidiary of Astrazeneca)
  • Merck
  • Mitsubishi Tanabe Pharma Corporation
  • Panacea Biotec
  • Pfizer
  • Sanofi Pasteur
  • Serum Institute of India
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll